These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 19903849)
1. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Arafa el-SA; Zhu Q; Barakat BM; Wani G; Zhao Q; El-Mahdy MA; Wani AA Cancer Res; 2009 Dec; 69(23):8910-7. PubMed ID: 19903849 [TBL] [Abstract][Full Text] [Related]
2. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro. Zhao JX; Liu H; Lv J; Yang XJ Eur Rev Med Pharmacol Sci; 2014; 18(17):2428-34. PubMed ID: 25268086 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458 [TBL] [Abstract][Full Text] [Related]
4. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Qamar L; Davis R; Anwar A; Behbakht K Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662 [TBL] [Abstract][Full Text] [Related]
5. Tangeretin, a citrus flavonoid, inhibits PGDF-BB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation. Seo J; Lee HS; Ryoo S; Seo JH; Min BS; Lee JH Eur J Pharmacol; 2011 Dec; 673(1-3):56-64. PubMed ID: 22040922 [TBL] [Abstract][Full Text] [Related]
6. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling. Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764 [TBL] [Abstract][Full Text] [Related]
7. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137 [TBL] [Abstract][Full Text] [Related]
8. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Asselin E; Mills GB; Tsang BK Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739 [TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Cai G; Wang J; Xin X; Ke Z; Luo J Int J Oncol; 2007 Sep; 31(3):657-62. PubMed ID: 17671694 [TBL] [Abstract][Full Text] [Related]
10. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer. Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552 [TBL] [Abstract][Full Text] [Related]
11. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway. Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371 [TBL] [Abstract][Full Text] [Related]
12. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells. Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Hayakawa J; Ohmichi M; Kurachi H; Kanda Y; Hisamoto K; Nishio Y; Adachi K; Tasaka K; Kanzaki T; Murata Y Cancer Res; 2000 Nov; 60(21):5988-94. PubMed ID: 11085518 [TBL] [Abstract][Full Text] [Related]
14. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474 [TBL] [Abstract][Full Text] [Related]
15. Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. Fekete M; Santiskulvong C; Eng C; Dorigo O Anticancer Res; 2012 Feb; 32(2):445-52. PubMed ID: 22287731 [TBL] [Abstract][Full Text] [Related]
16. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells. Schlosshauer PW; Li W; Lin KT; Chan JL; Wang LH Gynecol Oncol; 2009 Sep; 114(3):516-22. PubMed ID: 19576622 [TBL] [Abstract][Full Text] [Related]
17. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Qin X; Sun L; Wang J Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895 [TBL] [Abstract][Full Text] [Related]
18. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Rho SB; Kim BR; Kang S Gynecol Oncol; 2011 Jan; 120(1):121-7. PubMed ID: 21035837 [TBL] [Abstract][Full Text] [Related]
19. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077 [TBL] [Abstract][Full Text] [Related]
20. Sulforaphene Synergistically Sensitizes Cisplatin via Enhanced Mitochondrial Dysfunction and PI3K/PTEN Modulation in Ovarian Cancer Cells. Biswas R; Ahn JC; Kim JS Anticancer Res; 2015 Jul; 35(7):3901-8. PubMed ID: 26124336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]